Jump to content
FTO (Freedom to Operate) in the Pharmaceutical Industry / III. How to achieve freedom to operate (FTO)
FTO (Freedom to Operate) in the Pharmaceutical Industry / III. How to achieve freedom to operate (FTO)
Contents
Chapter
Expand
|
Collapse
Page
1–8
Titelei/Inhaltsverzeichnis
1–8
Details
9–11
I. Introduction
9–11
Details
12–15
II. Key features of innovation in the pharmaceutical industry
12–15
Details
A. Huge and growing market
Details
B. High R&D investment
Details
C. High Failure rates
Details
D. Significance of patents as safeguard of innovator’s profits
Details
16–33
III. How to achieve freedom to operate (FTO)
16–33
Details
A. Overviews of FTO analysis preparations
Details
B. Building up the multidisciplinary FTO team
Details
C. The FTO search
Details
D. Pharmaceutical Technical Considerations
Details
E. Pharmaceutical Patent Information
Details
F. Period of silence
Details
G. Interpreting potentially adverse patents
Details
1. Difference of analysis between patent and patent application
Details
a) The scope of possible amendment
Details
b) Patentability
Details
2. File wrapper
Details
3. Doctrine of equivalents
Details
4. Status searches
Details
5. Patent term extension
Details
a) Term extension
Details
b) The scope of the extended patent
Details
H. Dealing with Adverse Patents
Details
1. Legal / IP management strategies
Details
a) License-in / Cross-license
Details
b) Oppose / invalidate third-party patents
Details
c) Seek compulsory license
Details
2. R&D strategies
Details
a) Modify product
Details
b) Invent around
Details
3. Business Strategies
Details
a) Wait-and-see
Details
b) Merge and/or acquire (M&A)
Details
34–57
IV. Structure and operation of FTO-licensing markets in the pharmaceutical industry
34–57
Details
A. FTO-licensing and EU competition law
Details
1. Licensing and technology transfer in general
Details
2. Royalty obligations in general
Details
3. Previous view on royalty obligation based on the price of the final product
Details
a) Case: Windsurfing International v Commission of the European Communities
Details
b) The previous Guidelines: Commission Regulation (EC) No. 773/2004
Details
c) License
Details
4. Royalties on products produced without using licensed technology
Details
a) Issues
Details
b) TTBER and the Guidelines on the issue
Details
c) Analysis on Article 4(1)(a) and relevant Guidelines
Details
(i) Competitors Prices
Details
(ii) Launch Timing and Sequence
Details
(iii) Cross-national spillovers
Details
(iv) Products Characteristics
Details
(v) Country Fixed Effects
Details
B. FTO-licensing between a venture business company for innovative drug development and a pharmaceutical company
Details
1. Introduction
Details
2. Reasons for the growing interest for licensing-in/out the pharmaceutical industry
Details
3. The type of drugs a venture business company develops
Details
4. The reality of licensing-in/out
Details
5. Analysis of current situation
Details
a) Needs/Seeds mismatching
Details
b) Unclear relationship of right
Details
c) Geographical distance
Details
d) Risk of insufficient FTO performed by a bio-venture company
Details
6. Some proposals
Details
a) More attention to the FTO analysis and licensing by a bio-venture company
Details
b) The FTO by a pharmaceutical company at earlier stage of the development
Details
58–60
V. Conclusion
58–60
Details
61–64
List of Works Cited
61–64
Details
Durchsuchen Sie das Werk
Geben Sie ein Keyword in die Suchleiste ein
CC-BY
Access
FTO (Freedom to Operate) in the Pharmaceutical Industry , page 16 - 33
III. How to achieve freedom to operate (FTO)
Autoren
Hirotaka Nonaka
DOI
doi.org/10.5771/9783845294018-16
ISBN print: 978-3-8487-5221-8
ISBN online: 978-3-8452-9401-8
Chapter Preview
Chapter Preview
Share
Download PDF
Download citation
RIS
BibTeX
Copy DOI link
doi.org/10.5771/9783845294018-16
Share by email
Video schließen
Share by email Nomos eLibrary
Recipient*
Sender*
Message*
Your name
Send message
This site is protected by reCAPTCHA and the Google
Privacy Policy
and
Terms of Service
apply.
